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Abstract
RNA Interference (RNAi) effectors have been used to inhibit rogue RNAs in mammalian cells. However, rapidly evolving
sequences such as the human immunodeficiency virus type 1 (HIV-1) require multiple targeting approaches to prevent the
emergence of escape variants. Expressed long hairpin RNAs (lhRNAs) have recently been used as a strategy to produce
multiple short interfering RNAs (siRNAs) targeted to highly variant sequences. We aimed to characterize the ability of
expressed lhRNAs to generate independent siRNAs that silence three non-contiguous HIV-1 sites by designing lhRNAs
comprising different combinations of siRNA-encoding sequences. All lhRNAs were capable of silencing individual target
sequences. However, silencing efficiency together with concentrations of individual lhRNA-derived siRNAs diminished from
the stem base (first position) towards the loop side of the hairpin. Silencing efficacy against HIV-1 was primarily mediated by
siRNA sequences located at the base of the stem. Improvements could be made to first and second position siRNAs by
adjusting spacing arrangements at their junction, but silencing of third position siRNAs remained largely ineffective.
Although lhRNAs offer advantages for combinatorial RNAi, we show that good silencing efficacy across the span of the
lhRNA duplex is difficult to achieve with sequences that encode more than two adjacent independent siRNAs.
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Introduction
RNA Interference (RNAi) is a highly conserved biological
pathway in eukaryotes where gene silencing is mediated by a
double-stranded RNA (dsRNA) trigger [1]. Exploitation of the
RNAi pathway has lead to fundamental new tools for genetics
research and for sequence-specific therapeutic approaches aimed
at suppressing rogue cellular genes or viral-associated RNAs.
RNAi has traditionally been induced in mammalian cells through
the exogenous introduction of synthetic short interfering RNAs
(siRNAs) [2], or through the use of RNA Pol III or Pol II gene
constructs which express 21–29 bp short hairpin RNAs (shRNAs)
[3–6]. Expressed short hairpins resemble pre-microRNAs (pre-
miRNAs), which are part of the endogenous microRNA (miRNA)
pathway [7,8]. The targeting of highly mutable sequences, such as
genomic and sub-genomic RNAs from infectious agents, remains a
significant hurdle for the use of RNAi-based therapeutics. In
particular, the human immunodeficiency virus type 1 (HIV-1),
which replicates using an error-prone reverse transcriptase, has
been shown to escape the silencing effects of shRNAs. Resistant
viral variants emerge easily in cell culture experiments, even when
targeting highly conserved sequences [9–11]. Effective targeting of
rapidly evolving targets requires a combinatorial approach, which
is analogous to Highly Active Antiretroviral Therapy (HAART)
[reviewed by [12,13]].
The targeting of many sites simultaneously using RNAi has
been attempted with multiple shRNA expression units, where each
unit is expressed from a RNA Pol III promoter [14–16] or RNA
Pol II promoter [17]. Similarly, concatenated miRNA mimics
expressed from a single RNA Pol II promoter have been shown to
suppress simultaneously up to three separate target sequences
[6,18,19]. Although RNAi-mediated silencing in lower eukaryotes
can be achieved efficiently by introducing precursor dsRNAs
comprising more than 150 base pairs (bp), intracellular presence of
dsRNA of greater than 30 bp leads to a strong innate
immunostimulatory response, which is mediated by dsRNA-
activating protein kinase (PKR) and 29–59 oligoadenylate synthe-
tase [20]. A re-evaluation of long dsRNA greater than 30 bp in
mammalian cells has shown that safe and effective gene-specific
silencing can be achieved when dsRNA is expressed from DNA-
based expression cassettes [21–26]. Although a complete charac-
terization of how intracellular dsRNAs are discriminated remains
to be established, intracellularly expressed dsRNA seem capable of
evading cytoplasmic activators of the type 1 interferon response
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processing by the RNAse III endonuclease Dicer theoretically
allows for the generation of multiple siRNAs, providing a
mechanism of combinatorial targeting of rapidly-evolving RNAs.
The silencing caused by lhRNAs may also be more effective than
that resulting from a single unique siRNA derived from an
individual shorter (,30 bp) expressed shRNA.
Akashi et al. showed that (,50 bp) long hairpin RNAs (lhRNAs)
expressed from tRNA
Val and U6 RNA Pol III promoters
generated multiple siRNAs [24]. We and other have shown that
similar constructs were capable of suppressing Hepatitis B Virus
(HBV) [26], Hepatitis C Virus (HCV) [29] and HIV-1 [30–33]
targets. To date, lhRNAs capable of producing more than two
independent siRNAs have only been used against contiguous
target sequences. Since ,60 bp hairpin RNAs should be capable
of providing a substrate for at least three catalytic reactions
involving Dicer, we have examined the possibility of introducing
three distinct non-contiguous target sequences that, if processed by
Dicer, are capable of generating highly-effective independent
siRNA species. To determine the ability of targeting disparate
regions in the HIV-1 genome, we generated a panel of ,69 bp
U6-lhRNA expression cassettes, each consisting of a different
arrangement of three adjacent 21-mer putative siRNA sequences.
The siRNA sequences chosen were previously characterized as
highly effective anti-HIV-1 shRNAs targeted to Tat/Env, Tat/
Rev and Vif open reading frames [4,34]. We show that all
combinations of lhRNAs were capable of significant knockdown
against individual target sequences. However, silencing efficiency
together with individual siRNA concentrations diminished from
stem base to loop side along the length of the duplex. We present
here a thorough characterisation of the efficacy of expressed
lhRNAs designed to generate multiple siRNAs targeted to non-
contiguous siRNA-susceptible regions of HIV-1.
Results
Design of anti HIV-1 lhRNA-expressing plasmids
Three sites that have been previously shown to be effective for
RNAi-mediated inhibition of HIV-1 were selected. These include
shRNAs targeted to sites within two separate overlapping reading
frames of the HIV-1 genome: Tat/Rev (tat) and Rev/Env (rev) [4].
The third site includes a sequence within the Vif open reading
frame (vif) [34] (Fig. 1A). Long hairpin RNAs of approximately
69 bp (with a 5 nt terminal loop) were designed to be transcribed
from a U6 RNA Pol III promoter such that three 21–23 bp
siRNAs could potentially be generated by Dicer cleavage (Fig. 1B).
LhRNA and shRNA expression cassettes were designed to encode
siRNA precursors targeted to each of these 3 HIV-1 sites (Fig. 1C).
G:U wobble base pairs were included at regular intervals by
adjusting sequences in the sense strand to facilitate propagation of
the lhRNA-encoding cassettes in E. coli. To control for changes in
strand bias, similar G:U mismatches were made to each shRNA
(Fig. 1C). These changes have previously been shown to have no
impact on RNAi knockdown efficacy [24,26] and may help in
suppressing the innate immune response to dsRNA [24]. The
lhRNAs were therefore intended to be capable of serving as
substrates to form siRNAs against each of the tat, rev and vif HIV-1
targets. By targeting three viral sites simultaneously, the lhRNAs
have a possible therapeutic benefit of limiting viral escape.
Although this is an important theoretical advantage, there is
some evidence to suggest that Dicer processing of lhRNAs may not
be equal across the span of the duplex [26,33] and that Dicer
favours the production of siRNAs generated from the hairpin stem
base. Thus, to assess the importance of the position of the tat, rev
and vif siRNA-encoding sequences within the anti HIV-1 lhRNAs,
their efficacy when ordered as first, second or third within the stem
duplex was assessed.
Assessing anti HIV-1 efficacy of expressed lhRNA
sequences in cell culture
Initially, to assess efficacy against HIV-1 in vitro, HEK293 cells
were cotransfected with lhRNA-or shRNA-expressing vectors
together with the dual luciferase psiCheck vector encoding a
reporter/HIV-1 fusion gene (Fig. 2A). Four target vectors were
generated, which each included tat, rev, vif or a combination of tat-
rev-vif HIV-1 21-mer targets downstream of the Renilla luciferase
open reading frame (ORF). Measurement of Renilla:Firefly
luciferase allowed convenient and accurate measurement of the
in situ efficacy of the hairpin sequences. When using the luciferase
reporter that includes all three HIV-1 targets (psiCheck tat-rev-vif),
highly effective knockdown of approximately 90% was achieved
for each of the lhRNA- and shRNA-encoding plasmids (Fig. 2B).
When the tat sequence alone was inserted downstream of the
Renilla luciferase reporter gene, the shRNA tat vector was capable
of 90% inhibition of reporter gene expression, and as expected, the
shRNA rev and shRNA vif vectors caused no decrease in reporter
fusion gene activity (Fig. 2C). lhRNA expression cassettes
diminished Renilla-tat gene activity by approximately 30–50%
and lhRNA tat-rev-vif was the most efficient. When similar
assessment was carried out on the psiCheck rev and psiCheck vif
targets, the shRNAs induced specific silencing and lhRNAs with
the siRNA-encoding sequences located at the base of the stem
duplex were most efficient. A 63 bp lhRNA targeted to the HIV-1
TAR loop, showed no inhibitory activity against any of the targets.
These data support our previous observations using lhRNAs to
inhibit HBV [26] and HIV [31,33] replication and indicate that
there is a bias of silencing efficiency that diminishes from the base
of the stem to loop side of the duplex RNA.
Detection of processed antiviral hairpin sequences
The spacing arrangement of each individual siRNAs within the
long hairpin duplex is such that 4 ‘‘neutral’’ bases were placed
between each 21-mer sequence. This arrangement was recently
determined as optimal for two siRNAs placed within an extended
shRNA [32]. To analyse primary transcripts and processed
products of the anti HIV-1 hairpin expression cassettes a northern
blot hybridisation was carried out. RNA was extracted from
transfected HEK293 cells and Figure 3A shows the signals
obtained after hybridisation to probes that were complementary
to the putative mature processed tat, rev or vif siRNA guide strands.
Mature products of each of the shRNA expression cassettes were
detectable as bands of approximately 22–23 nt in size. Processing
of the shRNA primary transcripts to produce siRNA appeared to
occur more effectively than that of lhRNA expression cassettes for
guide strands at the base of the duplex, which may be due to better
recognition by Dicer for the shRNA than the lhRNA (Fig. 3A).
The band representing precursors for construct lhRNA vif-tat-rev
was larger than the precursor bands of the other two lhRNAs,
suggesting that read-through transcription is occurring beyond the
polyT termination signal. Detection with the vif probe suggests
that the production of siRNAs were not impaired for lhRNA vif-
tat-rev (at least in the first position). For the lhRNAs, guide strands
derived from the duplex stem base region of the lhRNA expression
cassettes were present in highest concentration, while those that
originated from the second and third positions of the lhRNA stem
were only detected for the lhRNA rev-vif-tat construct, in
decreasing order of concentration. It is possible that the probes
are not detecting the second or third siRNA because of
Long Hairpin RNA Processing
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this further, we used two 14-mer locked-nucleic acid (LNA)
probes, LNA-tat-1 and LNA-tat-2, which were partially or fully
complementary to the tat siRNA respectively (Fig. 3B). LNA-tat-2
was designed to fully complement any siRNAs generated by three
Dicer processing reactions that are 21-bases apart. The results
show that only the tat siRNA guide derived from the shRNA tat or
lhRNA tat-rev-vif could be detected by both probes, which supports
the theory that there is a considerable drop in siRNA
concentration as Dicer processes along the lhRNA duplex.
Effect of spacing between siRNA-encoding sequences of
the lhRNAs on silencing efficacy
To assess the effect of the spacing between siRNA-encoding
sequences on silencing efficiency, the lhRNA rev-vif-tat encoding
cassette was modified by insertion or deletion of 1–4 bases at each
of the junctions of the siRNA-encoding sequences (Fig. 4A). When
these modified lhRNA rev-vif-tat-derived expression cassettes were
transfected into HEK293 cells together with psiCheck tat-rev-vif
target, the silencing efficacy of each of the RNAi effector
sequences was similar, and approximately 95% silencing was
achieved (Fig. 4B). Slightly diminished efficacy was observed for
lhRNA rev-vif-tat e. This sequence had a deletion of 2 bp at the rev-
vif junction, which may influence processing and silencing efficacy
of the siRNA originating from the stem base. Assessment of
silencing of individual tat, rev and vif targets again showed that the
silencing was greatest for each target cognate of the siRNA derived
from the stem base of the lhRNA sequence (Fig. 4C). When using
the psiCheck rev target, knockdown of approximately 90% was
achieved by all of the hairpins except for lhRNA rev-vif-tat e, which
again showed diminished efficacy. No rev siRNA guide was
observed for lhRNA rev-vif-tat e by northern blot when probing for
rev (Fig. 4D), explaining the lack of inhibitory activity for this
lhRNA species when detecting effects at the first position (for rev,
Fig 3C). Diminished knockdown of reporter gene activity was
observed when the fused target corresponded to the second
position siRNA within the lhRNA duplex. However, the different
spacing arrangements resulted in significant variation in silencing
efficiency at this position. Interestingly, lhRNA rev-vif-tat e was
more effective than each of the other lhRNA rev-vif-tat cassettes
against the vif target. The 2 bp deletion at the rev-vif junction of
lhRNA rev-vif-tat e may be the most optimal spacing arrangement
for the vif siRNA sequence, which is in the second position.
Inhibition of the reporter-tat target (third position) was largely
ineffective for all of the lhRNA variants. The results suggest that
there exists considerable leeway in improving first and second
Figure 1. HIV-1 C subtype genome with sites targeted by lhRNA and shRNAs. A. Organization of HIV-1 subtype C genome indicating open
reading frames (ORFs) together with the 59 and 39 long terminal repeats (LTRs). Arrows show the sites targeted by each of shRNA vif, shRNA tat and
shRNA rev, as well as the lhRNAs. B. Schematic illustration of lhRNAs comprising 69 bp in the stem. G:U pairings are indicated as corrugated sense
strand. A sequence of 2 U residues that are derived from the transcription termination signal is shown. The intended mechanism of transcription and
processing of the lhRNAs to form 3 anti HIV-1 siRNAs is illustrated. C. Sequences and predicted structure of lhRNAs and shRNAs. The order of the
siRNA-encoding sequences within the lhRNAs is indicated along the extent of the duplex. G:U and U:G pairings are indicated with an arrowhead.
doi:10.1371/journal.pone.0002602.g001
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third position siRNAs are unlikely to be dramatically improved by
these modifications.
Inhibition of HIV-1 replication in infected cells in culture
To assess the efficacy of lhRNA sequences in a culture model of
HIV-1 infection, U87.CD4.CCR5 cells were transfected with
various lhRNA expression plasmids followed by viral challenge
with a South African R5-tropic subtype C HIV-1 isolate, FV5
(accession: 05ZAFV5). Knockdown was assessed by determining
p24 antigen levels and viral RNA genome equivalents (Fig. 5A) in
the culture supernatant at day 6 post-infection. Of the lhRNA
expression cassettes, lhRNA tat-rev-vif was most effective and
achieved inhibition of markers of viral replication by 60–70%.
shRNA tat was the most effective of the shRNA expression
cassettes and effected inhibition of approximately 60%. Both
lhRNA rev-vif-tat and shRNA rev were less effective whereas lhRNA
vif-tat-rev and shRNA vif respectively had weak or no inhibitory
effect on HIV-1 replication in this cell culture model. The efficacy
of silencing was also observed longitudinally, again indicating the
ineffective silencing by shRNA vif and lhRNA vif-tat-rev (Fig. 5B) .
Silencing by the second and third position siRNAs from lhRNA
vif-tat-rev are not contributing to the inhibition of HIV-1
replication, but the first position is the most significant for the
other 2 lhRNAs. Analysis of the sequences of the targets from the
FV5 isolate (Fig. 5C) reveals that the putative hairpin-derived vif
guide is not perfectly complementary to its viral cognate and
includes 3 G:U wobble mismatches. Although, shRNA vif was
originally chosen as it proved to be effective at inhibiting viral
progression and replication [34], it is possible that inhibiting vif
may not immediately influence p24 output. To determine if the
FV5 vif target sequence is refractory to silencing by shRNA vif and
respective vif-containing lhRNAs, a psiCheck luciferase reporter
vector was constructed containing HXB2 and FV5 vif shRNA
target sequences. When compared to the inhibition of the HXB2
vif target, shRNA vif or lhRNA vif-tat-rev was unable to inhibit the
Figure 2. Knockdown of target-reporter fusion gene expression. A. psiCheck-derived vectors that include indicated HIV-1 target sequences
inserted downstream of the Renilla luciferase ORF. The control Firefly luciferase cassette, present on the same plasmid, is also shown. Both cassettes
are under control of constitutively active transcription regulatory elements: Herpes simplex virus thymidine kinase (HSV TK) and Simian virus 40
(SV40) promoters. B. Average normalized ratios of the Renilla:Firefly luciferase activity when cells were transfected with psiCheck tat-rev-vif dual
luciferase reporter plasmid together with lhRNA- or shRNA-encoding plasmid vectors. C. Average normalized ratios of the Renilla:Firefly luciferase
activity when cells were transfected with psiCheck tat, psiCheck rev or psiCheck vif dual luciferase reporter plasmids together with lhRNA- or shRNA-
encoding plasmid vectors. The average values from three independent transfection experiments, with standard deviations, are given (*, p,0.05, t-
test, relative to mock transfected control).
doi:10.1371/journal.pone.0002602.g002
Long Hairpin RNA Processing
PLoS ONE | www.plosone.org 4 July 2008 | Volume 3 | Issue 7 | e2602FV5 target (Fig 5D). These data may explain why no viral
inhibition was observed for shRNA vif and lhRNA vif-tat-rev
(Figs 5A,B). The results of the challenge assay support the previous
reporter knockdown data that lhRNA knockdown efficacy is
primarily mediated by first position siRNA sequences located at
the base of the duplex stem.
Discussion
The lhRNAs designed in this study were developed specifically
to generate three separate functional siRNAs targeting known
non-adjacent siRNA-susceptible regions of HIV-1. Such an
approach is of tremendous value to efforts aimed at combinatorial
RNAi strategies, where the targeting of highly mutagenic
sequences, such as HIV-1, may help prevent the emergence of
resistant viral variants [12,13]. Combinatorial RNAi approaches
applied to date include the use of multiple RNA Pol III promoters
to express shRNAs [15,35,36]. Various combinatorial shRNA-
expression systems have been shown to delay effectively the
emergence of shRNA-resistant HIV-1 in cell culture [15,36],
proving in principle the efficacy of a multiple targeting RNAi
strategy against a rapidly evolving target. However, there are
reservations about the use of multiple RNA Pol III expression
cassettes. Firstly, little is known about the long-term stability and
efficacy of such a system: adjacent repeat sequences may
recombine when delivered by viral vectors or when stably
expressed in rapidly dividing cells [36]. Secondly, and more
importantly, the use of multiple highly active RNA Pol III
promoters can potentially flood the cell with shRNAs and abrogate
the natural microRNA biogenesis pathway, leading to unwanted
toxicities [37–39]. It is clear that the presence of several
therapeutic hairpin species will require careful dosing in order to
achieve the desired levels of silencing.
To date, lhRNAs expressed from RNA Pol III promoters have
been used against a single contiguous target sequence in
mammalian cells. Previous reports targeting HCV and HIV have
suggested that lhRNAs (.50 bp) can adequately inhibit targets
harboring mutations that abrogate the silencing efficiency of 21 bp
shRNAs [24,30,33]. Yet, the efficacy of individually processed
siRNAs generated from expressed lhRNAs has not been
Figure 3. Northern blot analysis of RNA extracted from HEK293 cells that had been transfected with the indicated lhRNA and
shRNA-expressing plasmids. A. A single blot was probed with an oligonucleotide that was complementary to putative tat, rev and vif guide
sequences. B. The blot was probed with two 14-mer LNA oligonucleotides (LNA nucleotides underlined) which were complementary to the rev siRNA
guide sequence and adjacent nucleotides as indicated in the illustration. Both blots (from A and B) were stripped and reprobed with an
oligonucleotide complementary to U6 snRNA to control for equal RNA loading.
doi:10.1371/journal.pone.0002602.g003
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sons between lhRNAs and shRNA when targeted to the same
sequence. We have previously observed that ,60 bp U6-
expressed lhRNAs targeted to a contiguous sequence within
HBV generated siRNAs more efficiently from the base of the
hairpin stem, and this correlated with greater silencing efficacy
[26]. However, we could not rule-out the possibility that second or
third Dicer cleavage reactions generate siRNAs with ineffective
guide sequences. We suspect that an increased variance of the
siRNA pool and decreased siRNA concentration for second and
third position cleavage products is likely to compromise the
efficacy of siRNAs generated from lhRNAs that require more than
two Dicer reactions. By placing three known effective siRNA
sequences adjacent to each other along a 69 bp lhRNA duplex,
some general principles concerning the efficacy of expressed
lhRNAs for combinatorial RNAi have been deduced. By
comparing different combinations of adjacent siRNA sequences
within a lhRNA duplex, we show that sequences at the base of the
hairpin stem are preferentially processed into effective siRNAs,
and that the pattern of silencing appears to be independent of the
siRNA sequence within the duplex. There was an exception, as
construct lhRNA rev-vif-tat e (Fig 4) was not able to generate a
guide strand for the first position. Some sequence differences do
exist between lhRNA rev-vif-tat e and other lhRNA variants, and it
may be possible that the sequence of the 2 nt 39 overhang plays a
role in siRNA recognition within RISC. The Paz domain of Dicer
is known to have biased preference for different 39 overhang
sequences [40], and differential selection of processed siRNAs by
the analogous Argonaut 2 Paz domain may occur similarly
[41,42]. Overall, these data are in agreement with Dicer’s
preference for cleaving dsRNA duplex ends with 2-nt 39-OH
overhangs [40,43–45] but suggests that intracellular Dicer
processivity is relatively inefficient. This perhaps underscores the
function of human Dicer as a single-turnover enzyme specialized
in generating mature miRNAs from a single cleavage reaction.
Initially, the three independent siRNA-encoding sequences
were placed within the lhRNA duplex such that they were spaced
at 23 bp intervals. Recently, Liu et al [32] showed that extended
shRNAs with two independent siRNAs functioned optimally as
independent siRNAs when spaced 4 bp apart. However, in our
hands, such spacing arrangements were not necessarily optimal
and it remains difficult to make gross generalizations regarding
Dicer-processing positions along an expressed dsRNA duplex at
this stage. Nevertheless, improvements in multiple targeting can be
achieved by further investigating the addition or deletion of
nucleotides at the siRNA junctions along the duplex. For one of
the lhRNAs, lhRNA rev-vif-tat, efficient processing of the second
siRNA was observed, albeit at reduced concentrations. If arranged
correctly, augmented knockdown can be achieved for two
independent siRNAs along a duplex, but this unlikely to be
possible for three siRNAs. Thus, one can envisage that use of
lhRNAs designed to efficiently inhibit at least two independent
siRNA-susceptible regions may help to delay the onset of HIV-1
escape variants, especially when targeting only conserved
Figure 4. Effect of nucleotide spacing between tat, rev and vif siRNA-encoding sequences on silencing efficacy. A. Schematic illustration of
hairpin sequences with boundaries between tat, rev and vif duplexes indicated. The sequences and numbers of bases inserted or deleted at the junctions
of the RNAi effecter-encoding sequences are indicated for each of lhRNA rev-vif-tat at ol h R N Arev-vif-tat g. B. Average normalized Renilla:Firefly luciferase
activity determined 48 hours after transfecting HEK293 cells with the psiCheck tat-rev-vif target together with each of lhRNA rev-vif-tat at ol h R N Arev-vif-
tat g. C. Average normalized Renilla:Firefly luciferase activity determined 48 hours after transfecting HEK293 cells with the psiCheck tat,p s i C h e c krev or
psiCheck vif target together with each of lhRNA rev-vif-tat at ol h R N Arev-vif-tat g. Results are given as the average values with standard deviations from
three independent transfection experiments. (*, p,0.05, t-test, relative to mock transfected control). Mock transfected cells received the empty backbone
U6+1p l a s m i dD. Northern blot analysis of RNA extracted from HEK293 cells that had been transfected with the indicated lhRNA and shRNA-expressing
plasmids.Theblotwasprobedwithanoligonucleotidethatwascomplementarytoputativerevguidesequence.Theblotwasstrippedandreprobedwith
an oligonucleotide complementary to U6 snRNA to control for equal RNA loading.
doi:10.1371/journal.pone.0002602.g004
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cleavage of an lhRNA will be present in sufficient concentration to
produce three effective siRNAs. We therefore provide a note of
caution for the use of lhRNAs containing more than two adjacent
siRNA sequences aimed at effective combinatorial RNAi.
Nevertheless, lhRNAs in combination with other multiple RNAi
effector sequences, such as Pol II-expressed multiple miRNA
precursors [14,18,19], are likely to provide an effective means of
targeting rapidly evolving sequences such as HIV-1.
In conclusion, we show that RNA Pol III-expressed lhRNAs are
capable of producing independent siRNAs that induce significant
knockdown of non-contiguous siRNA-susceptible regions of HIV-
1. Importantly, the position and arrangement of the siRNA-
encoding sequences along the lhRNA duplex plays an important
role in determining the overall efficacy of the lhRNA in target
suppression. Nonetheless, by optimizing the particular arrange-
ment of siRNA-encoding sequences along the lhRNA duplex,
effective multiple targeting is possible for up to two Dicer
processing reactions. We therefore provide a useful framework
for investigating the use of RNA Pol III-expressed lhRNAs aimed
at effective combinatorial RNAi in mammalian cells.
Materials and Methods
Target plasmids
The psiCheck target plasmids were prepared by directed
insertion of the XhoI-NotI digested HIV-1 PCR fragments into
the plasmid psiCheck2 (Promega, WI, USA) such that the target
sequences were within the 39 UTR of Renilla Luciferase. The
individual shRNA target sequences were amplified by PCR from
pNL4-3 template [47] using the following primers: sh tat target F
59- GAT CTC GAG AGT GTT GCT TTC ATT GCC AA-39
(29 nt), sh tat target R 59-GAT CGC GGC CGC GCA TTA CAT
GTA CTA CTT ACT GCT T-39 (37 nt). sh rev target F 59-GAT
CTC GAG AAG GTG GAG AGA GAG ACA GA-39 (29 nt), sh
rev target R 59-GAT CGC GGC CGC CAC CAA TAT TTG
Figure 5. HIV-1 challenge assay. U87.CD4.CCR5 cells were transfected with plasmids expressing the indicated hairpins and then subjected to
infection with an equivalent of TCID50 1000 particles of the HIV-1 FV5 viral isolate. Concentrations of HIV-1 p24 in the culture supernatant and viral
particle equivalents (A) were determined 6 days after infection. Results are expressed as the means with standard deviations of three independent
experiments (*, p,0.05, t-test, relative to mock transfected control). B. Replication kinetics of a representative experiment included in (A). C.
Sequence of lhRNA- and shRNA-derived tat, rev and vif guide sequences and complementary regions targeted within FV5 and HXB2 HIV-1 isolates.
Mismatches between the putative guide and target sequences are shown. Sequence numbering is based on isolate HXB2, accession K03455. D.
Knockdown of FV5 vif and HXB2 vif target-reporter fusion gene expression by shRNA vif and representative lhRNAs in HEK293 cells. Results are
expressed as the means with standard deviations of three independent experiments (*; p,0.05, t-test, between annotated samples).
doi:10.1371/journal.pone.0002602.g005
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ATT TCA AGG AAA GCT AAG GA-39 (29 nt), sh vif target R
59-GAT CGC GGC CGC AAT GCC AGT CTC TTT CTC
CT-39 (32 nt). To generate a product consisting of all three target
sites adjacent to one another, complementary oligonucleotides
were treated with polynucleotide kinase (Promega, WI, USA),
annealed, and cloned directly into the XhoI-NotI sites of
psiCheck2. To facilitate screening, an EcoRV site was inserted
within each annealed dsDNA insert. The oligonucleotides used
include: target tat-rev-vif (+)5 9- GAT CTC GAG GCG GAG
ACA GCG ACG AAG AGC TTG CCT GTG CCT CTT CAG
CTA CC-39 (53 nt) and target tat-rev-vif (2)5 9-GAT CGC GGC
CGC GTG GGA TGT GTA CTT CTG AAC AAG GTA GCT
GAA GAG GCA CAG GC-39 (58 nt). Similarly, psiCheck clones
were constructed for a HXB2 and FV5 vif target: target FV5-vif
(+)5 9-TCG AGA TAT CGT TCA GAA GTA CAT ATT CCA
TGC -39 and target FV5-vif (2)5 9-GGC CGC ATG GAA TAT
GTA CTT CTG AAC GAT ATC -39; target HXB2-vif (+)5 9-
TCG AGA TAT CGT TCA GAA GTA CAC ATC CCA CGC -
39 and target HXB2-vif (2)5 9-GGC CGC GTG GGA TGT
GTA CTT CTG AAC GAT ATC -39.
Long hairpin RNA and short hairpin RNA expression
plasmids
The procedure for generating Pol III U6 shRNA cassettes has
been previously described [4,48]. A similar 2 step PCR approach
was used to produce the lhRNA and shRNA vectors complemen-
tary to the HIV-1 vif, tat, and rev genes. The first amplification was
carried out with a universal U6 forward primer and first lhRNA or
shRNA reverse primer with U6 promoter plasmid DNA as
template. The amplified product was used as template for a PCR
step with a second lhRNA or shRNA reverse primer and again the
universal U6 forward primer. The sequence of the U6 universal
forward primer was 59- CTA ACT AGT GGC GCG CCA AGG
TCG GGC AGG AAG AGG G-39. Sequences of the reverse
primers for the amplifications were as follows: lhRNA tat-rev-vif R1
59- CTT GAA ATG GAA TGT ATA CCT CTA AAC AAG
GCA GCC GAA GAG ACA CAG ACA AGC CCT TCA TCA
CTA TCC CCG CGG TGT TTC GTC CTT TCC ACA A -39
(94 nt), lhRNA tat-rev-vif R2 59- AAA AAA GCG GAG ACA
GCG ACG AAG AGC TTG CCT GTG CCT CTT CAG CTA
CCT TGT TCA GAA GTA CAC ATC CCA CTC TCT TGA
AAT GGA ATG TAT A -39 (94 nt). lhRNA rev-vif-tat R1 59- CTT
GAA GCC CTT CAT CAC TAT CCC CGC AAA TGG AAT
GTA TAC CTC TAA ACA AGG CAG CCG AAG AGA CAC
AGA CGG TGT TTC GTC CTT TCC ACA A -39 (94 nt),
lhRNA rev-vif-tat R2 59- AAA AAA GCC TGT GCC TCT TCA
GCT ACC TTG TTC AGA AGT ACA CAT CCC ACT TGC
GGA GAC AGC GAC GAA GAG CTC TCT TGA AGC CCT
TCA TCA C -39 (94 nt). lhRNA vif-tat-rev R1 59- CTT GAA GGC
AGC CGA AGA GAC ACA GAC AAG CCC TTC ATC ACT
ATC CCC GCA AAT GGA ATG TAT ACC TCT AAA CGG
TGT TTC GTC CTT TCC ACA A -39 (94 nt), lhRNA vif-tat-rev
R2 59- AAA AAA GTT CAG AAG TAC ACA TCC CAC TTG
CGG AGA CAG CGA CGA AGA GCT TGC CTG TGC CTC
TTC AGC TAC CTC TCT TGA AGG CAG CCG AAG A -39
(94 nt). shRNA tat R1 59- CTC TTG AAG CCC TTC ATC ACT
ATC CCC GCG GTG TTT CGT CCT TTC CAC AA -39
(50 nt), shRNA tat R2 59- AAA AAA GCG GAG ACA GCG
ACG AAG AGC TCT CTT GAA GCC CTT CAT CAC -39
(48 nt). shRNA rev R1 59- CTC TTG AAG GCA GCC GAA
GAG ACA CAG ACG GTG TTT CGT CCT TTC CAC AA -39
(50 nt), shRNA rev R2 59- AAA AAA GCC TGT GCC TCT TCA
GCT ACC TCT CTT GAA GGC AGC CGA AGA -39 (48 nt).
shRNA vif R1 59- CTC TTG AAA TGG AAT TGT ATA CCT
CTA AAC GGT GTT TCG TCC TTT CCA CAA -39 (50 nt),
shRNA vif R2 59- AAA AAA GTT CAG AAG TAC ACA TCC
CAC TCT CTT GAA ATG GAA TGT ATA -39 (48 nt). The
sequences for variants of lhRNA rev-vif-tat were: lhRNA rev-vif-tat b
R1 59- CTC TTG AAG CCC TTC ATC ACT ATC CCC GCA
AAT GGA ATG TAT ACC TCT AAA CAG GCA GCC GAA
GAG ACA CAG ACG GTG TTT CGT CCT TTC CAC AA-39
(95 nt), lhRNA rev-vif-tat bR 25 9- AAA AAA GCC TGT GCC
TCT TCA GCT ACC TGT TCA GAA GTA CAC ATC CCA
CTT GCG GAG ACA GCG ACG AAG AGC TCT CTT GAA
GCC CTT CAT C-39 (91 nt). lhRNA rev-vif-tat cR 15 9- CTC
TTG AAG CCC TTC ATC ACT ATC CCC GCT AAA TGG
AAT GTA TAC CTC TAA ACA GGC AGC CGA AGA GAC
ACA GAC GGT GTT TCG TCC TTT CCA CAA -39 (96 nt),
lhRNA rev-vif-tat cR 25 9- AAA AAA GCC TGT GCC TCT TCA
GCT ACC TGT TCA GAA GTA CAC ATC CCA CTT AGC
GGA GAC AGC GAC GAA GAG CTC TCT TGA AGC CCT
TCA TCA -39 (93 nt). lhRNA rev-vif-tat dR 15 9- CTC TTG AAG
CCC TTC ATC ACT ATC CCC GCT TAA ATG GAA TGT
ATA CCT CTA AAC AGG CAG CCG AAG AGA CAC AGA
CGG TGT TTC GTC CTT TCC ACA A -39 (97 nt), lhRNA rev-
vif-tat dR 25 9- AAA AAA GCC TGT GCC TCT TCA GCT
ACC TGT TCA GAA GTA CAC ATC CCA CTT AAG CGG
AGA CAG CGA CGA AGA GCT CTC TTG AAG CCC TTC
ATC A -39 (94 nt). lhRNA rev-vif-tat eR 15 9- CTT GAA GCC
CTT CAT CAC TAT CCC CGC GCG CAA ATG GAA TGT
ATA CCT CTA AAC GGC AGC CGA AGA GAC ACA GAC
GGT GTT TCG TCC TTT CCA CAA -39 (96 nt), lhRNA rev-
vif-tat eR 25 9- AAA AAA GCC TGT GCC TCT TCA GCT
ACC GTT CAG AAG TAC ACA TCC CAC TTG CGC GCG
GAG ACA GCG ACG AAG AGC TCT CTT GAA GCC CTT
CAT CAC -39 (96 nt). lhRNA rev-vif-tat fR 15 9- CTT GAA GCC
CTT CAT CAC TAT CCC CGC TTA AAT GGA ATG TAT
ACC TCT AAA CAA GGC AGC CGA AGA GAC ACA GAC
GGT GTT TCG TCC TTT CCA CAA -39 (96 nt), lhRNA rev-
vif-tat fR 25 9- AAA AAA GCC TGT GCC TCT TCA GCT
ACC TTG TTC AGA AGT ACA CAT CCC ACT TAA GCG
GAG ACA GCG ACG AAG AGC TCT CTT GAA GCC CTT
CAT CAC -39 (96 nt). lhRNA rev-vif-tat gR 15 9- CTT GAA GCC
CTT CAT CAC TAT CCC CGC TTA AAT GGA ATG TAT
ACC TCT AAA CGA AGG CAG CCG AAG AGA CAC AGA
CGG TGT TTC GTC CTT TCC ACA A -39 (97 nt), lhRNA rev-
vif-tat gR 25 9- AAA AAA GCC TGT GCC TCT TCA GCT
ACC TTC GTT CAG AAG TAC ACA TCC CAC TTA AGC
GGA GAC AGC GAC GAA GAG CTC TCT TGA AGC CCT
TCA TCA C -39 (97 nt). The 63 bp lhRNA control plasmid,
lhRNA TAR, which was designed to target an irrelevant site
which included the HIV-1 TAR stem-loop (complementary to
positions 454–512, numbering according to HIV-1 HXB2
sequence, accession K03455), has been previously described
[26]. For all lhRNA constructs, each pair of primers had an
overlapping sequence of 19 bases that enabled extension of the
PCR product to generate a U6 promoter lhRNA cassette with a
RNA Pol III transcription termination signal [48]. Amplified PCR
products were ligated to a T/A cloning vector (pTZ57R/T,
Fermentas, WI, USA) to generate pTZ-U6 lhRNA and shRNA
plasmids. Sequences were confirmed by standard procedures.
Cell culture
The human embryonic kidney cell line, HEK293, was
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM,
BioWhittaker, MD, USA) supplemented with 10% heat inactivat-
ed fetal calf serum (FCS, Delta Bioproducts, Johannesburg, SA) at
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U87.CD4.CCR5 (NIH AIDS Research and Reference Reagent
Program), was maintained in DMEM supplemented with 15%
heat inactivated FCS, 50 IU/mL Penicillin/50 mg/mL Strepto-
mycin mix (Gibco, BRL, UK), 1 mg/mL Puromycin (Merck,
London, UK), 300 mg/mL G418 (Sigma, MO, USA) and 1% L-
glutamine (Sigma, MO, USA) at 37uC and 5% CO2.
Transfections
Transfections were carried out using a ratio of 1 mL
Lipofectamine2000 (Invitrogen, CA, USA) to 1 mg total DNA
per well according to the manufacturer’s instructions. Media was
changed 24 hours post transfection, and analysis of cells was
carried out 24 hours thereafter. Equivalent transfection efficiencies
were verified by fluorescence microscopy by cotransfecting a
plasmid that constitutively produces enhanced green fluorescent
protein (pCI-eGFP) [49].
To evaluate the effects of the lhRNA and shRNA encoding
plasmids on a reporter target, HEK293 cells were seeded 24 hours
prior to transfection at 120 000 cells per well in 24 well culture
dishes. HEK293 cells were transfected with 150 ng of target
plasmid, 750 ng of lhRNA or shRNA encoding plasmid and
100 ng of pCI-eGFP.
To determine the induction of IFN response-related genes,
HEK293 cells were seeded as described above and transfected
with 900 ng of lhRNA or shRNA encoding plasmid and 100 ng
pCI-eGFP per well. Control double stranded RNA, poly (I:C)
(Sigma, MO, USA), was transfected at equivalent amounts to the
hairpin encoding plasmids.
For Northern blot analysis HEK293 cells were seeded at 80%
confluency in 10 cm culture dishes 24 hours prior to transfection.
Cells were transfected using Lipofectamine with 16 mg of lhRNA
or shRNA encoding plasmid, 3 mg of target plasmid, and 1 mg
pCI-eGFP.
To assess the effects of the lhRNA encoding plasmids on a
subtype C HIV-1 primary isolate in an infection challenge assay,
U87.CD4.CCR5 cells (NIH HIV/AIDS Reagent and Reference
Program) were washed with 16PBS, treated for 5 minutes with
16trypsin, counted as described above and seeded 24 hours prior
to transfection at 100 000 cells per well in 12 well culture dishes
using DMEM supplemented with 15% heat inactivated FCS only.
The following day, cells were co-transfected with 900 ng of lhRNA
encoding plasmid and 100 ng of pCI-GFP per well as described
above.
Dual luciferase assay
These were carried out according to the manufacturer’s
instructions (Promega, WI, USA) using a Veritas dual-injection
luminometer (Turner Biosystems, C A, USA). Target-specific
Renilla luciferase expression was normalized to background firefly
luciferase expression. Average expression ratios for a control
plasmid containing the U6 promoter was set to 100%, and relative
expression levels for other samples calculated accordingly. Two
independent experiments in triplicate were performed and the
data are expressed as the mean6standard deviation.
Viral propagation and challenge assay
FV5 is a primary HIV-1 CCR5-utilizing subtype C virus that was
isolated from a drug-naı ¨ve HIV-positive AIDS patient admitted to
the Johannesburg HospitalAIDSclinic, and propagated by standard
PBMC co-culture techniques. The co-receptor tropism of FV5 was
established genotypically by automated sequencing of the V3 loop of
the viral env gene (accession 05ZAFV5), and confirmed phenotyp-
ically by MT-2 fusion assay. Twenty four hours post-transfection,
U87.CD4.CCR5 cells were infected with FV5 using a TCID50 1000.
Twenty four hours post infection cells were washed three times using
16PBS and fresh media was added. At days 0 (day of washing), 3, 5
and 6, 100 mL of supernatant was collected per well and analysed by
ELISA (Murex Biotech LTD, Dartford, UK) for p24 antigen
production as a marker of viral replication.Viral RNAwas extracted
from 300 mL of day 6 supernatant using the COBAS Ampliprep
instrument(Roche,Germany),followedbyaviralloadassaywiththe
COBAS Amplicor (Roche, Germany) according to manufacturer’s
specifications.Day0 p24 datawascompleted andinall casesnoviral
p24 protein or RNA was detected indicating that all residual
infecting virus had been removed from the cultures.
Northern blot analysis
Total RNA was extracted from HEK293 cells using TriRea-
gent
TM (Sigma, MO, USA) according the manufacturer’s
instructions 48 hours post-transfection. Twenty-five micrograms
of RNA was resolved on urea denaturing 15% polyacrylamide gels
and blotted onto nylon membranes. RNA molecular weight
markers, which were radioactively labeled as described below,
were run alongside the cellular RNA. Blots were hybridized to
three DNA oligonucleotides (probes tat, rev and vif) to detect
products of hairpin processing. These were complimentary to
regions spanning the antisense sequence of the long hairpin.
Probes were labeled at their 59 ends with [c-
32 P] ATP and T4
polynucleotide kinase. After purification using standard proce-
dures, they were hybridized to immobilized RNA, exposed to X-
ray film and then stripped and reprobed. An oligonucleotide
sequence complementary to U6 small nuclear RNA was used as a
control to verify equal loading of the cellular RNA. Probe
oligonucleotide sequences were as follows: probe tat:5 9-GCG
GAG ACA GCG ACG AAG AGC TT-39; probe rev:5 9-GCC
TGT GCC TCT TCA GCT ACC TT-39; probe vif:5 9-GTT
CAG AAG TAC ACA TCC CAC TT-39; and U6 small nuclear
RNA probe: 59-TAG TAT ATG TGC TGC CGA AGC GAG
CA-39. The LNA probe sequences were as follows: probe LNA-tat-
1:5 9-ACT TGC GGA GAC AG-39; probe LNA-tat-2:5 9-GCG
CGC GGA GAC AG-39. The LNA nucleotides are underlined.
Statistics
Statistical calculations were determined using the GraphPad
Prism software package (GraphPad, Software, Inc., CA, USA).
Statistical difference was considered significant when p,0.05 and
was determined using either an unpaired Student’s t-test or by
ANOVA.
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